about
The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA ("ecstasy") in humansDuloxetine inhibits effects of MDMA ("ecstasy") in vitro and in humans in a randomized placebo-controlled laboratory studyDopamine denervation of the prefrontal cortex increases expression of the astrocytic glutamate transporter GLT-1MDMA enhances emotional empathy and prosocial behaviorMonoamine transporter and receptor interaction profiles of a new series of designer cathinones.Bupropion, methylphenidate, and 3,4-methylenedioxypyrovalerone antagonize methamphetamine-induced efflux of dopamine according to their potencies as dopamine uptake inhibitors: implications for the treatment of methamphetamine dependence.Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans.Blockade of the 5-HT transporter contributes to the behavioural, neuronal and molecular effects of cocaine.Interactions of Cathinone NPS with Human Transporters and Receptors in Transfected Cells.Effects of the α₂-adrenergic agonist clonidine on the pharmacodynamics and pharmacokinetics of 3,4-methylenedioxymethamphetamine in healthy volunteers.Differential effects of MDMA and methylphenidate on social cognition.Pharmacokinetic and pharmacodynamic effects of methylphenidate and MDMA administered alone or in combination.α₁-Adrenergic receptors contribute to the acute effects of 3,4-methylenedioxymethamphetamine in humans.In Vitro Characterization of Psychoactive Substances at Rat, Mouse, and Human Trace Amine-Associated Receptor 1.Serotonin Transporter-Independent Actions of the Antidepressant Vortioxetine As Revealed Using the SERT Met172 Mouse.Sex differences in the effects of MDMA (ecstasy) on plasma copeptin in healthy subjects.Pharmacology of MDMA- and Amphetamine-Like New Psychoactive Substances.Pharmacological profiles of aminoindanes, piperazines, and pipradrol derivatives.Neural circuits in goal-directed and habitual behavior: Implications for circuit dysfunction in obsessive-compulsive disorderThe SERT Met172 Mouse: An Engineered Model To Elucidate the Contributions of Serotonin Signaling to Cocaine ActionAberrant habit formation in the Sapap3-knockout mouse model of obsessive-compulsive disorder
P50
Q28240897-8191508E-8422-4BBB-84EA-578997156EA2Q28483370-308B7854-4DBC-4247-96AE-592541D3DAC4Q33786459-98309CB7-4817-4788-B5C0-B572E837753FQ34375625-66477B41-13A7-4385-8988-5A21BADC8D5EQ34387724-42DBA5B2-8700-4175-A063-67543738940AQ34756340-8A3706F2-AC38-4944-A846-8A6C1296B4FBQ36252777-486F8E00-9852-4CE1-A46B-D66FACD2A019Q38430705-B3009B48-0C17-48D5-9A14-7B9E4AE2E5F0Q39703486-CE144F56-CD80-4592-81A1-2C343DAF2D54Q43842146-A654CDB6-FC09-4BD9-8B6F-D6D226FBB20EQ43842167-3067A06D-E03E-4FF1-A020-7C53373E3892Q44959633-D355C675-9FDA-48AA-BF40-9A5203256F4FQ46076536-73ADA62F-BDFC-4C87-9640-FC1329EB1990Q46607679-858E7861-7F67-444B-BC12-F7515C39893BQ47951673-15689D63-4BEA-4156-98BA-DA304410BA46Q51444042-D9930D50-2569-4EC6-865B-EB06184741A8Q52597275-9C5EAEA0-60D2-4FD6-964D-D8DAE6250A90Q53068499-AD38ABF3-7006-490D-95E8-92A621950008Q91948169-51EBD648-70F8-472E-9181-D3280EE39C2AQ92003177-99DC8DA0-C8AB-4160-84F8-7A0A9531C8E6Q92710492-07D4BA60-4E7A-42BC-BF8C-29F7C564B8E8
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Linda D Simmler
@ast
Linda D Simmler
@en
Linda D Simmler
@es
Linda D Simmler
@nl
Linda D Simmler
@sl
type
label
Linda D Simmler
@ast
Linda D Simmler
@en
Linda D Simmler
@es
Linda D Simmler
@nl
Linda D Simmler
@sl
prefLabel
Linda D Simmler
@ast
Linda D Simmler
@en
Linda D Simmler
@es
Linda D Simmler
@nl
Linda D Simmler
@sl
P1053
R-4128-2016
P106
P21
P31
P3829
P496
0000-0003-3512-4057